AstraZeneca Places $420M Bet On Mass. Biotech Startup
The investment in Moderna Therapeutics Inc., which is trying to create medicines that use messenger RNA to provoke cellular responses, includes a $240 million upfront infusion, $180 million in milestone payments and royalties on any products that make it to market.
Under the five-year deal, Moderna will be responsible for design...
To view the full article, register now.